Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of Rifaximin In The Treatment of HBV Associated Acute-on-Chronic Liver Failure Patients With Mild to Moderate Hepatic Encephalopathy

NCT05786859 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT05786859
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05786859 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of Rifaximin In The Treatment of HBV Associated Acute-on-Chronic Liver Failure Patients With Mild to Moderate Hepatic Encephalopathy
Lead sponsor
Sun Yat-sen University
Phase
Phase 1
Overall status
Unknown status
Start date
March 9, 2023
Completion date
October 31, 2025
Enrollment
124 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

effect of drug, hbv, hepatic encephalopathy, hepatitis b, liver failure, acute on chronic, rifaximin